Effect of omega3 supplementation in women with polycystic ovary syndrome

Effect of omega3 supplementation on oxidated low density lipoprotein ,interleukin6 and hsCRP in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112318564N1

Enrollment

Registered

2012-08-11

Start date

2012-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome

Interventions

Intervention 1: intervention: capsules of fish-oil (3 g/d) for 2 month. Intervention 2: Capsules of placebo (3 g/d) for 2 month.

Placebo

intervention: capsules of fish-oil (3 g/d) for 2 month

Capsules of placebo (3 g/d) for 2 month

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: females 20-40 years; PCOS diagnostic according to Roterdam criteria and BMI>25; no history about intake of any drug during the last 3 months that may affect the insulin sensitivity or hormonal profile such as: oral contraceptives, glucocorticoids, ovulation induction agents, anti diabetic and anti obesity drugs, estrogenic, antiandrogenic or anti hypertensive medication; not being in any diet in the last 3month; do not have any addiction to tobacco and alcohol; do not taking a Omega-3 supplement in the last 3 months; do not be menopaused; do not use anti-coagulant medicine; do not use anti-depression medication and do not be diabetic and hypothyroidism. Exclusion criteria: essentially needs for intake of OCP to treatment; do not will to be in the study; do not obey the protocols of the study and do not digest more than 20% of supplements.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Oxidated low density lipoprotein. Timepoint: Before and after intervention. Method of measurement: OxLDL ng/ml Elisa kit -.;SHBG. Timepoint: Before and after intervention. Method of measurement: Elisa kit nmol/L SHBG- Elisa kit.;Free androgen index. Timepoint: Before and after intervention. Method of measurement: Testosteron/SHBG.;Testosteron. Timepoint: Before and after intervention. Method of measurement: Elisa kit nmol/L Testosteron.;Interleukin 6. Timepoint: Before and after intervention. Method of measurement: IL6 pg/ml Elisa kit.;HsCRP. Timepoint: Before and after intervention. Method of measurement: mg/L hsCRP - Elisa kit.	—

Measure

Time frame

Oxidated low density lipoprotein. Timepoint: Before and after intervention. Method of measurement: OxLDL ng/ml Elisa kit -.;SHBG. Timepoint: Before and after intervention. Method of measurement: Elisa kit nmol/L SHBG- Elisa kit.;Free androgen index. Timepoint: Before and after intervention. Method of measurement: Testosteron/SHBG.;Testosteron. Timepoint: Before and after intervention. Method of measurement: Elisa kit nmol/L Testosteron.;Interleukin 6. Timepoint: Before and after intervention. Method of measurement: IL6 pg/ml Elisa kit.;HsCRP. Timepoint: Before and after intervention. Method of measurement: mg/L hsCRP - Elisa kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNiloofar Vaziri

Institute for Reproductive Sciences, Research and Cinical Center for Infertility

niloofar_vzr@ssu.ac.ir+98 35 1824 7085

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026